Cellectar Biosciences, Inc. (CLRB) vs Citius Pharmaceuticals, Inc. (CTXR)
A side-by-side comparison of Cellectar Biosciences, Inc. and Citius Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CLRB
Cellectar Biosciences, Inc.
$1.67HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT
CTXR
Citius Pharmaceuticals, Inc.
$0.52HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT
Total return — CLRB vs CTXR
growth of $100 · dividends reinvested · last 10yCLRB -100.0% (-55.5%/yr)CTXR -99.8% (-46.2%/yr)CTXR compounded faster over this window
Log scale — wide-divergence pair
CLRB CTXR
CLRB vs CTXR: by the numbers
- •CTXR is the larger company ($14M vs $13M market cap).
- •Both run net losses; CLRB's is the smaller (0.00% vs -651.27% net margin).
Metrics side by side
Valuation
| Metric | CLRB | CTXR |
|---|---|---|
| P/S ratio | N/A | 2.01 |
| P/B ratio | 0.45 | 0.21 |
Profitability
| Metric | CLRB | CTXR |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | -651.27% |
| ROE | -74.73% | -69.47% |
| ROIC | -74.94% | -67.62% |
Growth (annualized)
| Metric | CLRB | CTXR |
|---|---|---|
| Total return CAGR (5Y) | -60.51% | -60.04% |
Frequently asked
- How have CLRB and CTXR total returns compared?
- Over the past 10 years, CLRB delivered -55.35% and CTXR delivered -46.34% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.